FDG PET (positron emission tomography) predicts osteosarcoma outcome:
This article was originally published in Clinica
Executive Summary
Positron emission tomography (PET) may provide a powerful prognostic tool in predicting outcomes for patients with osteosarcoma, a form of bone cancer that often affects children. In a 29-patient German study, researchers found that use of PET with the radiopharmaceutical 18F-fluorodeoxyglucose (FDG) could help identify patients who have a poorer prognosis and who may be suitable for more aggressive therapy. The researchers, led by Christiane Franzius, of the University of Munster, found that the higher the initial FDG uptake in tumour, the poorer was the prognosis. Dr Franzius' study was reported at this month's Society of Nuclear Medicine meeting in Los Angeles, California. Between 500 to 1,000 new cases of osteosarcoma are estimated to occur in the US annually.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.